You are here: Industry Insights > Asthma

News List

World COPD deaths rise 12 percent in 15 years pharmatimes
August 18, 2017
Study found that the number of people dying from COPD up nearly 12 percent over a 15-year period.
Teva Announces FDA Approval of QVAR RediHaler americanpharmaceuticalreview
August 11, 2017
Teva Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has approved QVAR RediHaler inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Teva gets FDA approval for easier-to-use inhaler pharmatimes
August 08, 2017
The FDA has approved Teva’s QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma.
NICE u-turn backs use of Teva’s asthma biologic pharmatimes
July 24, 2017
The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair fiercepharma
July 21, 2017
There’s still no word on whether Teva has landed AstraZeneca CEO Pascal Soriot or if he is staying put, as later reports said. But in the meantime, the drugmaker got some good news Thursday on the respiratory front.
NICE recommends Cinqaero (reslizumab) for treatment of severe asthma europeanpharmaceuticalreview
July 21, 2017
The National Institute for Health and Care Excellence (NICE) in England has recommended Teva Pharmaceutical Industries Ltd’s Cinqaero (reslizumab) in its Final Appraisal Determination (FAD).
Asia-Pacific asthma market will hit $6 billion by 2023, says GBI Research europeanpharmaceuticalreview
June 12, 2017
The Asia-Pacific (APAC) asthma therapeutics market, which covers India, China, Australia, South Korea and Japan, is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
New medicine shows potential to reduce oral steroid use in severe asthma patients europeanpharmaceuticalreview
May 31, 2017
A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.
Spiriva Respimat inhalation spray improves breathing for people with asthma regardless of BMI or all cphi-online
May 25, 2017
In all analyses, people experiencing uncontrolled asthma symptoms saw improvements in their breathing by adding Spiriva Respimat to an ICS or combination ICS/LABA.
GSK 'real world' drug test has second success in asthma biospectrumasia
May 15, 2017
The study showed the drug, which is marketed as Relvar in Europe, was superior in controlling symptoms of asthma compared to usual care, based on a standardized questionnaire filled out by patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page